# A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

> **NCT05442684** · PHASE3 · WITHDRAWN · sponsor: **CanSino Biologics Inc.**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
- **BIOLOGICAL:** Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation
- **BIOLOGICAL:** mRNA-based COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05442684
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-30
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial protocol was not approved by the regulatory authorities.
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442684, "A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05442684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*